Asset profile
Aclidinium bromide · Tudorza Pressair
Small molecule
Evidence outlook
Approved: Chronic Obstructive Pulmonary Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
47 competitors in this universe: 7 direct rivals (same mechanism and indication), 4 same-class, 36 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Aclidinium Bromide (Tudorza Pressair): this drug | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Olodaterol / Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Umeclidinium (Incruse Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), M3 muscarinic acetylcholine receptor | ||
| Umeclidinium / Vilanterol | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Ba253BINEB | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Ipratropium | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| PT001 | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Pirenzepine (topical) | Phase 2 | Small molecule | Muscarinic acetylcholine receptor (M3), Muscarinic M1 receptor (antagonist) | ||
| Benralizumab (Fasenra) | Approved | Monoclonal antibody | IL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophils | ||
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | ||
| Depemokimab | Approved | Monoclonal antibody | IL-5 | ||
| Ensifentrine (Ohtuvayre) | Approved | Small molecule | PDE3/PDE4 |
…and 32 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.